Nucleostemin和HDAC1在卵巢肿瘤中的表达及意义

目的:研究核干细胞因子(Nucleostemin, NS)和组蛋白去乙酰化酶1(HDAC1)在卵巢肿瘤及正常卵巢组织中的表达,并分析其表达与临床指标的关系及两者间的表达相关性。方法:选择2010年至2017年我院卵巢石蜡标本60例,其中卵巢肿瘤50例,正常卵巢组织10例。应用免疫组化法检测NS与HDAC1的表达,并分析它们与年龄、肿瘤分期等临床指标的相关性。结果:在30例卵巢恶性肿瘤、10例卵巢交界性肿瘤、10例卵巢良性肿瘤组织中,NS表达的阳性率分别为93.3%、40%、20%,HDAC1的阳性率分别为90%、60%、20%。在正常卵巢组织中未见NS及HDAC1表达。在卵巢恶性肿瘤组中,NS和HDAC1的阳性表达率显著高于其他三组(P0.05),两者表达呈正相关(r=0.56, P0.05),且均与分化程度呈负相关(r=-0.76, P0.001; r=-0.53, P0.01),而与患者年龄、术前血清CA125水平、临床分期和病理类型无关。结论:NS和HDAC1倾向于卵巢恶性肿瘤中表达,且与卵巢恶性肿瘤的分化程度负相关。

Expression and Significance of Nucleostemin and HDAC1 in the Ovarian Tumor

ABSTRACT Objective: To study the expression of Nucleostemin (NS) and HDAC1 in ovarian tumor and normal ovarian tissues, and to analyze their relation with clinical indicators and the correlation of their expressions. Methods: From 2010 to 2017, 60 ovarian paraffin specimens were selected in our hospital, including 50 ovarian tumors and 10 normal ovarian tissues. Immunostaining was performed using antibodies for NS and HDAC1. Spearman rank correlation was employed for their relations with clinical indicators such as age and clinical stage and the correlation of their expression. Results: In 30 cases of malignant ovarian tumors, 10 cases of borderline ovarian tumors and 10 cases of benign ovarian tumors, the positive rates of NS expression were 93.3%, 40%, 20%, and the positive rates of HDAC1 were 90%, 60% and 20%, respectively. There was no expression of NS and HDAC1 in normal ovarian tissues. The positive rates of NS and HDAC1 in malignant ovarian tumors were significantly higher than those in the other three groups (P<0.05). There was a positive correlation between the expression of NS and HDAC1 (r=0.56, P<0.05) and their expression were negatively correlated with the degree of differentiation and (r=-0.76, P<0.001; r=-0.53, P<0.01) in malignant ovarian tumors, but not with age, preoperative serum CA125 level, clinical stage and pathological type. Conclusion: NS and HDAC1 tend to be expressed and are negatively correlated with the differentiation in malignant ovarian tumors.